UCB (OTCMKTS:UCBJF) Hits New 12-Month High – Here’s Why

Shares of UCB SA (OTCMKTS:UCBJF) hit a new 52-week high during trading on Wednesday . The stock traded as high as $345.39 and last traded at $341.1250, with a volume of 232 shares trading hands. The stock had previously closed at $335.24.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on UCBJF shares. Stephens reissued an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Barclays reaffirmed an “overweight” rating on shares of UCB in a report on Tuesday, January 6th. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of UCB in a research note on Monday, December 8th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, UCB has an average rating of “Buy”.

UCB Price Performance

The stock has a fifty day moving average of $305.24 and a 200-day moving average of $277.74. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.